Investigation of anti-tumoral effect and safety of combination therapy LD-GP (low dose gemcitabine and paclitaxel) therapy and sorafenib in patients with cisplatin-resistant advanced urothelial cancer.

Trial Profile

Investigation of anti-tumoral effect and safety of combination therapy LD-GP (low dose gemcitabine and paclitaxel) therapy and sorafenib in patients with cisplatin-resistant advanced urothelial cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2016

At a glance

  • Drugs Gemcitabine (Primary) ; Paclitaxel (Primary) ; Sorafenib (Primary)
  • Indications Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 26 Sep 2016 Status changed from active, no longer recruiting to completed.
    • 01 Oct 2015 Status changed from recruiting to active, no longer recruiting, as per results published in the Medical Oncology.
    • 02 Jul 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top